BACKGROUND: Tenofovir gel, an antiretroviral-based vaginal microbicide, reduced HIV acquisition by 39% in women in a recent randomized controlled clinical trial in South Africa. METHODS: To inform policy, we used a dynamical model of HIV transmission, calibrated to the epidemic in South Africa, to determine the population-level impact of this microbicide on HIV incidence, prevalence, and deaths and to evaluate its cost-effectiveness. RESULTS: If women use tenofovir gel in 80% or more of sexual encounters (high coverage), it could avert 2.33 (0.12 to 4.63) million new infections and save 1.30 (0.07 to 2.42) million lives and if used in 25% of sexual encounters (low coverage), it could avert 0.50 (0.04 to 0.77) million new infections and save 0.29 (0.02 to 0.44) million deaths, over the next 20 years. At US $0.50 per application, the cost per infection averted at low coverage is US $2392 (US $562 to US $4222) and the cost per disability-adjusted life year saved is US $104 (US $27 to US $181); at high coverage the costs are about 30% less. CONCLUSIONS: Over 20 years, the use of tenofovir gel in South Africa could avert up to 2 million new infections and 1 million AIDS deaths. Even with low rates of gel use, it is highly cost-effective and compares favorably with other control methods. This female-controlled prevention method could have a significant impact on the epidemic of HIV in South Africa. Programs should aim to achieve gel use in more than 25% of sexual encounters to significantly alter the course of the epidemic.
BACKGROUND:Tenofovir gel, an antiretroviral-based vaginal microbicide, reduced HIV acquisition by 39% in women in a recent randomized controlled clinical trial in South Africa. METHODS: To inform policy, we used a dynamical model of HIV transmission, calibrated to the epidemic in South Africa, to determine the population-level impact of this microbicide on HIV incidence, prevalence, and deaths and to evaluate its cost-effectiveness. RESULTS: If women use tenofovir gel in 80% or more of sexual encounters (high coverage), it could avert 2.33 (0.12 to 4.63) million new infections and save 1.30 (0.07 to 2.42) million lives and if used in 25% of sexual encounters (low coverage), it could avert 0.50 (0.04 to 0.77) million new infections and save 0.29 (0.02 to 0.44) million deaths, over the next 20 years. At US $0.50 per application, the cost per infection averted at low coverage is US $2392 (US $562 to US $4222) and the cost per disability-adjusted life year saved is US $104 (US $27 to US $181); at high coverage the costs are about 30% less. CONCLUSIONS: Over 20 years, the use of tenofovir gel in South Africa could avert up to 2 million new infections and 1 million AIDS deaths. Even with low rates of gel use, it is highly cost-effective and compares favorably with other control methods. This female-controlled prevention method could have a significant impact on the epidemic of HIV in South Africa. Programs should aim to achieve gel use in more than 25% of sexual encounters to significantly alter the course of the epidemic.
Authors: Timothy B Hallett; Ramzi A Alsallaq; Jared M Baeten; Helen Weiss; Connie Celum; Ron Gray; Laith Abu-Raddad Journal: Sex Transm Infect Date: 2010-10-21 Impact factor: 3.519
Authors: Brian G Williams; James O Lloyd-Smith; Eleanor Gouws; Catherine Hankins; Wayne M Getz; John Hargrove; Isabelle de Zoysa; Christopher Dye; Bertran Auvert Journal: PLoS Med Date: 2006-07 Impact factor: 11.069
Authors: David A Ross; John Changalucha; Angela In Obasi; Jim Todd; Mary L Plummer; Bernadette Cleophas-Mazige; Alessandra Anemona; Dean Everett; Helen A Weiss; David C Mabey; Heiner Grosskurth; Richard J Hayes Journal: AIDS Date: 2007-09-12 Impact factor: 4.177
Authors: Richard G White; Kate K Orroth; Judith R Glynn; Esther E Freeman; Roel Bakker; J Dik F Habbema; Fern Terris-Prestholt; Lilani Kumaranayake; Anne Buvé; Richard J Hayes Journal: J Acquir Immune Defic Syndr Date: 2008-03-01 Impact factor: 3.731
Authors: Rochelle P Walensky; Ji-Eun Park; Robin Wood; Kenneth A Freedberg; Callie A Scott; Linda-Gail Bekker; Elena Losina; Kenneth H Mayer; George R Seage; A David Paltiel Journal: Clin Infect Dis Date: 2012-04-03 Impact factor: 9.079
Authors: Todd J Johnson; Meredith R Clark; Theodore H Albright; Joel S Nebeker; Anthony L Tuitupou; Justin T Clark; Judit Fabian; R Tyler McCabe; Neelima Chandra; Gustavo F Doncel; David R Friend; Patrick F Kiser Journal: Antimicrob Agents Chemother Date: 2012-09-24 Impact factor: 5.191
Authors: Chris Beyrer; Anna-Louise Crago; Linda-Gail Bekker; Jenny Butler; Kate Shannon; Deanna Kerrigan; Michele R Decker; Stefan D Baral; Tonia Poteat; Andrea L Wirtz; Brian W Weir; Françoise Barré-Sinoussi; Michel Kazatchkine; Michel Sidibé; Karl-Lorenz Dehne; Marie-Claude Boily; Steffanie A Strathdee Journal: Lancet Date: 2014-07-22 Impact factor: 79.321
Authors: Tanuja N Gengiah; Leila E Mansoor; Michele Upfold; Anushka Naidoo; Nonhlanhla Yende-Zuma; Angela D M Kashuba; Quarraisha Abdool Karim; Salim S Abdool Karim Journal: AIDS Behav Date: 2014-05